scPharmaceuticals Inc. revised earnings guidance for the year 2022. Based on its current operating plan, the Company has adjusted its 2022 net loss to $38 to $41 million, a decrease over prior guidance of $43 to $48 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.91 USD | -2.49% | +11.40% | -37.64% |
05-14 | Transcript : ScPharmaceuticals Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | ScPharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.64% | 141M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- SCPH Stock
- News scPharmaceuticals Inc.
- ScPharmaceuticals Inc. Revises Earnings Guidance for the Year 2022